The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lakefront Biotherapeutics NV's share price is $28.08.
Lakefront Biotherapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $18.53. Hence, Lakefront Biotherapeutics NV's PS Ratio for today is 1.52.
The historical rank and industry rank for Lakefront Biotherapeutics NV's PS Ratio or its related term are showing as below:
GLPGF'
s PS Ratio Range Over the Past 10 Years
Min: 1.48 Med: 13.27 Max: 55.51
Current: 1.7
During the past 13 years, Lakefront Biotherapeutics NV's highest PS Ratio was 55.51. The lowest was 1.48. And the median was 13.27.
GLPGF's PS Ratio is ranked better than 87.18% of 928
companies
in the Biotechnology industry
Industry Median: 9.59
vs GLPGF: 1.70
During the past 12 months, the average Revenue per Share Growth Rate of Lakefront Biotherapeutics NV was 262.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 66.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.70% per year.
During the past 13 years, Lakefront Biotherapeutics NV's highest 3-Year average Revenue per Share Growth Rate was 69.90% per year. The lowest was -40.00% per year. And the median was 5.30% per year.
Back to Basics: PS Ratio
Lakefront Biotherapeutics NV (OTCPK:GLPGF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lakefront Biotherapeutics NV PS Ratio Related Terms
Lakefront Biotherapeutics NV PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lakefront Biotherapeutics NV's Share Price of today is $28.08. Lakefront Biotherapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lakefront Biotherapeutics NV (GLPGF) has a PS Ratio of 1.52 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 89% below median its historical median of 13.27. Over the past decade, Lakefront Biotherapeutics NV's PS Ratio has ranged from 1.48 to 55.51. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #119 out of 928 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Lakefront Biotherapeutics NV's PS Ratio too high?
Lakefront Biotherapeutics NV's current PS Ratio of 1.52 is 89% below median its 10-year median of 13.27. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 55.51. The Biotechnology industry median PS Ratio is 9.59. Lakefront Biotherapeutics NV's value of 1.52 is 84.2% below this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #119 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #119 out of 928 companies for PS Ratio. This places Lakefront Biotherapeutics NV in the top 13% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.59. Lakefront Biotherapeutics NV's value of 1.52 is 84.2% below this benchmark. Historically, Lakefront Biotherapeutics NV's own PS Ratio has ranged from 1.48 to 55.51 over the past decade. While the company's 10-year median is 13.27 vs. the industry median of 9.59, Lakefront Biotherapeutics NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.59, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current PS Ratio of 1.52 is 84.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median PS Ratio is 9.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current PS Ratio is 1.52, which is 89% below median its own 10-year median of 13.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Lakefront Biotherapeutics NV (GLPGF) has a current PS Ratio of 1.52. The stock's GF Value™ is $113.44, compared to a current price of $28.08 — trading 75.2% below its estimated fair value. The current PS Ratio is 1.52, which is 89% below median its 10-year median of 13.27 and 84.2% below the Biotechnology industry median of 9.59. Lakefront Biotherapeutics NV's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current PS Ratio is 1.52 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.08 is trading 75.2% below its estimated GF Value™ of $113.44.
Key valuation signals for GLPGF:
PS Ratio: 1.52 (89% below median its 10-year median of 13.27)
GF Value™: $113.44 vs. price of $28.08 (75.2% below fair value)
Industry Position: 84.2% below the Biotechnology median (#119 of 928)
No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
57GF Score
Get the complete analysis for GLPGF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLPGF has been successfully added to your 
